|
|
|
Subscribe
|
|
|
Contact
|
|
|
Cool insights to beat the summer heat
Don’t sweat the end-of-summer sizzle. Grab some shade (or a poolside seat) and dig into this issue of Access Point. You’ll find plenty of cool insights about white blood cell depletion — a protocol you may not use frequently, but which could be an invaluable tool for some patients. With a deep dive into run targets, anticoagulant options, and fluid balance, this issue sets you up for success with your patients this summer and throughout the year.
As always, if there are topics you want us to cover so you can make the most of your Spectra Optia™ Apheresis System and give your patients the best care possible, please let us know.
|
|
|
|
|
|
|
Let’s get specific: A closer look at white blood cell depletion
|
|
|
|
Patients with myeloproliferative disorders and leukemias face the risk of developing leukocytosis — an excessive buildup of white blood cells. White blood cell depletion (WBCD) can be a valuable tool in managing leukocytosis and preventing progression to a medical emergency. In this issue, we break down key aspects of the WBCD protocol on Spectra Optia to help you perform a safe, effective procedure.
|
|
|
|
Dear Access Point,
Sometimes after a white blood cell depletion procedure, the patient’s post-procedure white blood cell count doesn’t decrease as much as we expected. Why is that?
— Katie from Omaha, NE
Dear Katie,
As you probably know, the goal of a WBCD procedure is to reduce the number of white blood cells (WBCs) in a patient's peripheral blood. On Spectra Optia, WBCD is indicated for patients with leukocytosis who are at risk of leukostasis.1
The number of WBCs removed during a WBCD procedure can be influenced by several factors, including:
- The total number of WBCs in the blood that are available to be removed
- The mobilization of WBCs into the peripheral blood from the bone marrow and extramedullary sites such as the spleen and liver
- The total volume of blood processed during the procedure2
It’s also interesting to note that as WBCs are removed from the peripheral blood, WBCs from extramedullary sites (those outside the bone marrow) may move into that space,2 essentially replacing some of the depleted cells. This can result in the post-procedure WBC count being higher than expected.
|
|
|
|
If you have a specific question about the Spectra Optia system, let us know. We will feature a reader question in each Access Point edition. Be sure to tell us your first name, hometown, and state or province. Questions not featured will be answered directly via email.
|
|
|
|
|
|
|
|
|
|
|
|
Review how the procedure works on Spectra Optia with helpful procedure highlights and diagrams.
|
|
|
|
|
|
Did you know?
Spectra Optia can do calculations for you
When you’re preparing to perform a WBCD procedure on Spectra Optia, the system can calculate some values for you, based on simple inputs on the run values screen. Here are two examples.
|
|
|
|
1. If you enter the target fluid balance as a percentage (100 on the example screen shown here), the system calculates and displays the corresponding volume on the volume button (0 on the example screen). The reverse also applies: If you enter the target fluid balance as a volume, the system calculates it as a percentage.
|
|
|
|
2. If you enter the volume of replacement fluid you wish to use (660 on the example screen shown here), the system calculates the target fluid balance (100 and 0 on the example screen).
To learn more about performing WBCD procedures, review your Spectra Optia operator’s manual or contact your Terumo Blood and Cell Technologies representative.
|
|
|
|
September 16, 2025
October 25 to 28, 2025 | San Diego, CA
Live From Lakewood
- IMUGARD™ WB PLT Platelet Pooling Set Overview | September 18, 2025
- AC Management on the Spectra Optia™ Apheresis System | November 13, 2025
All Live From Lakewood sessions are scheduled for 12 p.m. MT. Learn more and register to attend any of these live and interactive webinar sessions from our headquarters in Lakewood, Colorado. If you would like to have a specific topic covered in one of these webinars, please send us an email.
Successions Workshops
Therapeutic Plasma Exchange | October 1, 2025 | St. Petersburg, FL
Red Blood Cell Exchange | October 2, 2025 | St. Petersburg, FL
Hosted by OneBlood
If you are interested in attending either of these workshops, please email Successions@TerumoBCT.com, and we will send you an invitation to register.
|
|
|
|
|
|
You're on the front lines of care, and we're here to assist.
|
|
|
|
|
|
|
|
could help you make the most of your Spectra Optia system and your relationship with
Terumo Blood and Cell Technologies to do even more for your patients.
|
|
|
|
|
|
1. Terumo Blood and Cell Technologies. White blood cell depletion. 2025. Part no. TS-OPTI-02784.
2. McLeod BC, Weinstein R, Winters JL, Szczepiorkowksi ZM, eds. Apheresis Principles and Practice. 3rd ed. Bethesda, MD: AABB Press; 2010:255.
Spectra Optia™ is either a registered trademark or trademark of Terumo BCT, Inc. in the United States and/or other countries. See TerumoBCT.com/Trademarks for details.
IMUGARD™ is either a registered trademark or trademark of Terumo Corporation or its affiliates.
|
|
|
|
©2025 Terumo BCT, Inc. | All Rights Reserved | TS-OPTI-02563 | TerumoBCT.com
|
|
|
|
|
